Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular determinants of drug response in TNBC cell lines.

Breast cancer research and treatment - 1 Jan 2020

Merrill Nathan M, Lachacz Eric J, Vandecan Nathalie M, Ulintz Peter J, Bao Liwei, Lloyd John P, Yates Joel A, Morikawa Aki, Merajver Sofia D, Soellner Matthew B

Abstract excerpt

PURPOSE: There is a need for biomarkers of drug efficacy for targeted therapies in triple-negative breast cancer (TNBC). As a step toward this, we identify multi-omic molecular determinants of anti-TNBC efficacy in cell lines for a panel of oncology drugs. METHODS: Using 23 TNBC cell lines, drug sensitivity scores (DSS3) were determined using a panel of investigational drugs and drugs approved for other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Drug Screening Assays, Antitumor

Share to Proteomics

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 31655920
DOI: 10.1007/s10549-019-05473-9
PMCID: PMC7323911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular determinants of drug response in TNBC cell lines.PMID 31655920Read ↗

Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseSemantic proximity Read ↗

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast CancerSemantic proximity Read ↗

Pan-Cancer Biomarker Analysis from the Cancer Dependency Map: A Blueprint for Precision OncologySemantic proximity Read ↗

Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockadeSemantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

Predicting Tumor Response to Drugs based on Gene-Expression Biomarkers of Sensitivity Learned from Cancer Cell LinesSemantic proximity Read ↗

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationSemantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.Semantic proximity Read ↗

Predicting Tumor Response to Drugs Based on Gene-expression Biomarkers of Sensitivity Learned From Cancer Cell LinesSemantic proximity Read ↗

Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.